secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001193125-22-303234
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Frequency Therapeutics expects FX-322-208 trial results in H2 Q1 2023
---------------------------------------------------------------------

- Posted updated corporate slide presentation on Dec 13, 2022.
- FX-322-208 Phase 2 trial results expected second half of Q1 2023.
- FX-322 is an investigational regenerative therapy for sensorineural hearing loss.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312522303234/0001193125-22-303234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312522303234/d425973d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-303234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer